ASTRO-LUNGevity Residents/Fellows in Radiation Oncology Seed Grant 2025 Request for Application

IMPORTANT NOTES TO READ BEFORE PROCEEDING

Potential applicants are encouraged to read this RFA in its entirety, including all eligibility requirements and other terms and conditions, before starting an application. Any applicant who is deemed ineligible for this award or does not follow the instructions for preparing the application will be disqualified and the application not reviewed.

The grant will be funded at a maximum of $50,000 for one year. Up to two grants will be awarded. Applications to this Seed Grant program might also be considered for other active 2025-2026 Seed Grant opportunities. One no-cost extension (NCE) may be considered by ASTRO and LUNGevity at their full discretion. However, the total project period may not exceed 2 years.

At the time of submission and throughout the duration of the award term, an applicant/awardee must be employed by a U.S. institution.

The application process will be managed through proposalCENTRAL.

Important Dates:

- March 10, 2025: Application deadline
- Early Summer 2025: Award notifications made
- July 1, 2025: Earliest award start date

Detailed instructions for applying for this award begin on page 4.

ASTRO
ASTRO is the premier radiation oncology society in the world. ASTRO's mission is to advance the practice of radiation oncology by promoting excellence in patient care, providing opportunities for educational and professional development, promoting research and disseminating research results and representing radiation oncology in a rapidly evolving health care environment. For more information about ASTRO, please visit https://www.astro.org/

LUNGEVITY FOUNDATION
LUNGevity Foundation is a 501(c)(3) philanthropy specifically focused on funding research for the early detection and effective treatment of lung cancer. LUNGevity's mission is to improve mortality rates of lung cancer patients through the development of protocols and tools for early detection of lung cancer, early intervention in the disease progression, and treatments, including targeted therapy and immunotherapy. LUNGevity focuses on translational science. For more information about LUNGevity Foundation, please visit www.LUNGevity.org.

ASTRO-LUNGevity Residents/Fellows in Radiation Oncology Seed Grant 2025 Request for Application

FUNDING OPPORTUNITY DESCRIPTION

Overview

The ASTRO-LUNGevity Residents/Fellows in Radiation Oncology Seed Grant is intended to foster and develop the research careers of residents and fellows interested in radiation-oncology related basic, translational and/or clinical research to benefit patients with lung cancer. The grant will be funded at a maximum of $50,000 for one year. Up to two grants will be awarded. Applications to this Seed Grant program might also be considered for other active 2025-2026 Seed Grant opportunities.

ELIGIBILITY

The general eligibility criteria are listed below. ASTRO has full discretion in any funding decision and is not obligated nor liable to issue any award to any eligible or ineligible applicants at any time.

Eligible Organizations

Higher Education Institutions

- Public/State Controlled Institutions of Higher Education
- Private Institutions of Higher Education

The following types of Higher Education Institutions are encouraged to apply as Public or Private Institutions of Higher Education:

- Hispanic-serving Institutions
- Historically Black Colleges and Universities (HBCUs)
- Tribally Controlled Colleges and Universities (TCCUs)
- Alaska Native and Native Hawaiian Serving Institutions
- Asian American Native American Pacific Islander Serving Institutions (AANAPISIs)

Nonprofits Other Than Institutions of Higher Education

- Nonprofits with 501(c)(3) IRS Status (Other than Institutions of Higher Education)
- Nonprofits without 501(c)(3) IRS Status (Other than Institutions of Higher Education)

Foreign Institutions

- Non-domestic (non-U.S.) Entities (Foreign Institutions) are **not** eligible to apply.
- Non-domestic (non-U.S.) components of U.S. Organizations are **not** eligible to apply.

Eligible Individuals (Residents/Fellows): Any candidate with the skills, knowledge, and resources necessary to carry out the proposed research as the Principal Investigator (PI) is invited to work with his/her mentor and organization to develop an application for support.

Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are especially encouraged to apply for ASTRO support. Multiple PIs are not allowed.

ASTRO-LUNGevity Residents/Fellows in Radiation Oncology Seed Grant 2025 Request for Application

Degree Requirements and Employment Status: Applicants must hold a doctorate degree such as PhD, MD/PhD, MD, DO, or other equivalent degree(s) and must be enrolled in a U.S. residency or fellowship at the time of application.

Level of effort: PIs are required to commit at least 75% of their full-time professional effort to research during the term of the grant. The remainder may be devoted to clinical or other pursuits consistent with the objectives of the grant.

ASTRO Membership: The applicant **must** be a current and active ASTRO member, or have submitted an application for ASTRO membership, as of the due date of the application. If selected, the PI will be required to maintain his/her membership throughout the duration of the grant.

COMMITMENT FROM THE APPLICANT

The applicant must designate a mentor at his/her Institution who will provide guidance and support for the research project. Mentors should be senior investigators with a minimum of R01 or equivalent level funding and provide a letter of support detailing their oversight and support.

- Meetings: If awarded, the PI is encouraged to attend at least one ASTRO Annual Meeting and present their research findings.
- LUNGevity Meeting: If awarded, the PI is required to attend the LUNGevity Fall Science Meeting and present their research findings.

COMMITMENT FROM THE APPLICANT'S MENTOR

- The mentor should be an accomplished investigator in the proposed research area and have a track record of success in training independent investigators.
- The mentor should have sufficient independent research support to cover the costs of the proposed research project in excess of the allowable costs of this award.
- The mentor must demonstrate, in writing, a commitment to the development of the applicant as a productive, independent investigator. It is expected that the mentor will meet with the PI at least weekly.
- Applicants may also nominate co-mentors as appropriate to the goals of the program.
- At least one mentor must be an active member of ASTRO.

COMMITMENT FROM THE APPLICANT'S AFFILIATED ELIGIBLE ORGANIZATION(S)

- If awarded, the host department will act as the fiscal intermediary. The Institution will administer the funds to the PI and be responsible for satisfying tax withholding, deposit and/or reporting requirements applicable to the payment of the award. The PI will be responsible for individual income taxes. The Institution will be required to provide sufficient additional funds to supplement salaries or supplies as needed for the research project. The Terms & Conditions for this Award are attached and should be shared with organizational officials before applications are submitted.

ASTRO-LUNGevity Residents/Fellows in Radiation Oncology Seed Grant 2025 Request for Application

- Any change in Institution, mentor, and chair or in the applicant's position that might affect their ability to successfully complete their training should be communicated as soon as possible so that appropriate action can be taken.
- When a mentor at the grantee's Institution is to be replaced, the Institution must submit a letter from the proposed mentor documenting 1) the need for substitution 2) the new mentor's qualifications for supervising the project and 3) the level of support for the applicant's career development.
- Only 1 grant can support the proposed research project. If independent funding is obtained for the same scope of work selected by ASTRO for this award the recipient must refuse either this or the competing award(s).

APPLICATION GUIDELINES

Submission: All applications are due by 11:59 pm Eastern time on March 10, 2025. Proposals will not be considered after the deadline. Applications must be submitted online using proposalCENTRAL and the document templates and requirements therein.

Application Instructions: It is critical that applicants follow the instructions. Conformance to the requirements in this RFA are required and strictly enforced. Applications that are out of compliance with these instructions may be delayed or not accepted for review.

Applicants must select **one** research focus area that best describes the scope of the research plan:

- Health Services/Health Equity/Disparities Focus
- Biology Focus
- Physics Focus
- Other Focus (not applicable to the above)

All materials must be prepared in English, single spaced, using a font size of 11 or 12 points. Smaller text in figures and charts is acceptable, once it is legible when the page is viewed at 100%. Arial or Times New Roman fonts are recommended. A minimum of one-half inch margins must be used on all page borders.

1. **Title Page**: Enter the Project Title, Discipline of Research, Research Focus Area, Proposal Budget, and indicate whether you have other research funding.

2. **Templates and Instructions**: Download RFA and templates.

3. **Enable Other Users to Access this Proposal**: Allow others (e.g. Institutional administrators or collaborators) to view, edit, or submit the proposal.

4. **Applicant**: Complete all required fields that include PI's name and contact information, ASTRO membership status and member ID, and level of effort (%) that will be allocated to the proposed research project.

ASTRO-LUNGevity Residents/Fellows in Radiation Oncology Seed Grant 2025 Request for Application

5. **PI Demographics**: Providing this information is optional and is not part of the review process.

6. **Institution and Contacts**: Provide the Institution's name, address and type of organization and requested contact information of the mentor and signing official.

7. **Key Personnel**: List and provide contact information for key persons.

8. **Scientific Abstracts, Impact Statement, Modalities and Common Scientific Outline (CSO) Codes**:
   - Provide a general audience abstract (non-technical) (2,000 characters including spaces max) and a technical abstract (3,000 characters including spaces max) that concisely describe the background, rationale, specific aims, experimental approach including model system and statistical approach, anticipated outcomes and impact of the project. Note: the general audience abstract will become public if the proposal is selected for funding, therefore, it should not include any proprietary information.
   - Impact Statement: Statement of Proposal's Benefit to lung cancer and radiation oncology research (1,000 characters including spaces max).
   - Select all relevant Modalities and CSO Codes that best represent the proposed research.

8. **Other Support**: List any additional research support that the PI currently holds. Include Project Title, Funding Source, Project Status, Award Number, Start and End Dates, Person Months, and Overlap.

9. **Research Assurances**: Indicate status of IRB/IACUC approvals as applicable, use of recombinant DNA, biohazardous materials, genetically engineered organisms, or fetal tissue.

10. **Application Documents**: Upload the below required application documents.

    - **Research Plan (6-page limit):** Project description to fit within the 1-year project period and should include:
      - Background
      - Preliminary data and figures (if applicable, but not required)
      - Specific aims
      - Experimental design/methods
      - Statistical analysis plan
      - Anticipated outcomes
      - Potential pitfalls and alternatives
      - Significance
      - Future directions

References must be included but will not count toward the 6-page limit.

• **Biosketches (5-page limit):** The applicant and lead mentor must each submit a biosketch including a list of relevant publications and currently funded research projects. DoD and NIH formats will be accepted. Biosketches for collaborators and research support staff are not required.

• **Budget and Budget Justification:** Submit a detailed budget (can be prepared using the NIH budget form e.g. PHS 398) and Budget Justification with a breakdown and description of the estimated costs. ASTRO will cover only direct costs. Funding cannot go towards supporting salaries of mentors or collaborators.

• **Mentoring plan (1-page limit):** A detailed mentoring plan from the applicant's mentor that outlines courses, lectures, meetings, and other ways to support the applicant and help increase likelihood of success must be included.

• **Letters of support (2):** Upload 2 letters of support. One must be from your mentor. The other can be from a collaborator. Letters of support from additional collaborators can be appended but are not required.

• **Institutional letter of support:** Upload one letter of support from the Institution or Department. This letter must indicate the level of commitment through matching funds or in-kind contribution from the Institution to this award. This letter should include a guarantee that the applicant will be afforded at least 75 percent protected time to perform research.

12. **Validate:** Review entire proposal for missing required information.

13. **Signature Page:** Before submitting the application, complete all fields within the signature page. A signature is required from both the Applicant/PI, the primary mentor, and a Signing Official from the applicant's Institution. **An electronic signature is required from both the Applicant/PI and a Signing Official from the applicant's institution.** Applications will not be considered for review if required signatures are missing.

APPLICATION REVIEW

All proposals will undergo a rigorous peer review by the ASTRO Grant Review Panel. Reviewers are members of the ASTRO Research Grants Evaluation Committee. A study section consisting of researchers with expertise in the areas and topics of each grant will review the application for scientific merit and appropriateness for funding. Final decisions will be subject to the approval of the ASTRO Board of Directors. If no suitable candidates are found, no awards may be issued.

- Each proposal will be scored by at least three qualified reviewers.
- Individuals who submit an application in response to this RFP or are designated as key personnel, including the mentor of an applicant, may not review applications for this RFP.
- ASTRO Reviewers will not score or discuss applications from their own institution or organization.

Review Criteria: In general, reviewers should evaluate the candidate's potential for making important contributions to the field of radiation oncology and lung cancer, taking into consideration the years of experience and the likely value of the proposed project as a vehicle for developing a successful, independent career. Selected proposals will have strong scientific merit and impact, and possess an innovative and transformative approach, and demonstrate potential for progression to the clinic or other significant impact.

Scored Review Criteria

Reviewers will score (rate 1-9) Factor 1 and 2 and will determine whether Factor 3 is sufficient or insufficient.

Factor 1: Importance of the Research

Significance

- Evaluate the importance of the proposed research in the context of current scientific challenges and opportunities, either for advancing knowledge within the field, or more broadly. Assess whether the application addresses an important gap in knowledge in the field, would solve a critical problem, or create a valuable conceptual or technical advance.
- Evaluate the rationale for undertaking the study, the rigor of the scientific background for the work (e.g., prior literature and/or preliminary data) and whether the scientific background justifies the proposed study.

Innovation

- Evaluate the extent to which innovation influences the importance of undertaking the proposed research. Note that while technical or conceptual innovation can influence the importance of the proposed research, a project that is not applying novel concepts or approaches may be of critical importance for the field.
- Evaluate whether the proposed work applies novel concepts, methods or technologies or uses existing concepts, methods, technologies in novel ways, to enhance the overall impact of the project.

Factor 2. Rigor and Feasibility

Approach.

- Evaluate the scientific quality of the proposed work. Evaluate the likelihood that compelling, reproducible findings will result (rigor) and assess whether

the proposed studies can be done well and within the timeframes proposed (feasibility).

Rigor

- Evaluate the potential to produce unbiased, reproducible, robust data.
- Evaluate the rigor of experimental design and whether appropriate controls are in place.
- Evaluate whether the sample size is sufficient and well-justified.
- Assess the quality of the plans for analysis, interpretation, and reporting of results.
- Evaluate whether the investigators presented adequate plans to address relevant biological variables, such as sex or age, in the design, analysis, and reporting.
- For applications involving human subjects or vertebrate animals, also evaluate:
  - the rigor of the intervention or study manipulation (if applicable to the study design).
  - whether outcome variables are justified.
  - whether the results will be generalizable or, in the case of a rare disease/special group, relevant to the particular subgroup.
  - whether the sample is appropriate and sufficiently diverse to address the proposed question(s).
- For applications involving human subjects, including clinical trials, assess the adequacy of inclusion plans as appropriate for the scientific goals of the research. Considerations of appropriateness may include disease/condition/behavior incidence, prevalence, or population burden, population representation, and/or current state of the science.

Feasibility

- Evaluate whether the proposed approach is sound and achievable, including plans to address problems or new challenges that emerge in the work. For proposed studies in which feasibility may be less certain, evaluate whether the uncertainty is balanced by the potential for major advances.
- For applications involving human subjects, including clinical trials, evaluate the adequacy and feasibility of the plan to recruit and retain an appropriately diverse population of participants. Additionally, evaluate the likelihood of successfully achieving the proposed enrollment based on age, racial, ethnic, and sex/gender categories.
- For clinical trial applications, evaluate whether the study timeline and milestones are feasible.

Factor 3: Expertise and Resources.

Investigator. Evaluate whether the investigator(s) have demonstrated background, training, and expertise, as appropriate for their career stage, to conduct the proposed work.

Environment. Evaluate whether the institutional resources are appropriate to ensure the successful execution of the proposed work.

Additional Review Criteria:
As applicable for the project proposed, reviewers will consider the following additional items while determining scientific and technical merit and in providing an overall impact score, but will not give scores for these items:

Protections for Human Subjects

- For research that involves human subjects but does not involve one of the categories of research that are exempt under 45 CFR Part 46, the committee will evaluate the justification for involvement of human subjects and the proposed protections from research risk relating to their participation according to the following five review criteria: (1) risk to subjects, (2) adequacy of protection against risks, (3) potential benefits to the subjects and others, (4) importance of the knowledge to be gained, and (5) data and safety monitoring for clinical trials.
- For research that involves human subjects and meets the criteria for one or more of the categories of research that are exempt under 45 CFR Part 46, the committee will evaluate: (1) the justification for the exemption, (2) human subjects involvement and characteristics, and (3) sources of materials. For additional information on review of the Human Subjects section, please refer to the NIH Guidelines for the Review of Human Subjects.
- When the proposed project involves human subjects and/or NIH-defined clinical research, the committee will evaluate the proposed plans for the inclusion (or exclusion) of individuals on the basis of sex/gender, race, and ethnicity, as well as the inclusion (or exclusion) of individuals across the lifespan (including children and older adults) to determine if it is justified in terms of the scientific goals and research strategy proposed. For additional information on review of the Inclusion section, please refer to the NIH Guidelines for the Review of Inclusion in Clinical Research.

Vertebrate Animals

- The committee will evaluate the involvement of live vertebrate animals as part of the scientific assessment according to the following criteria: (1) description of proposed procedures involving animals, including species, strains, ages, sex, and total number to be used; (2) justifications for the use of animals versus alternative models and for the appropriateness of the species proposed; (3) interventions to minimize discomfort, distress, pain and injury; and (4) justification for euthanasia method if NOT consistent with the American Veterinary Medical Association (AVMA) Guidelines for the Euthanasia of Animals. Reviewers will assess the use of chimpanzees as they would any other application proposing the use of vertebrate animals. For additional information on review of the Vertebrate

Animals section, please refer to the NIH Worksheet for Review of the Vertebrate Animal Section.

Biohazards

- Reviewers will assess whether materials or procedures proposed are potentially hazardous to research personnel and/or the environment, and if needed, determine whether adequate protection is proposed.

Budget and Period of Support

- Reviewers will consider whether the budget and the requested period of support are fully justified and reasonable in relation to the proposed research.

OTHER INFORMATION

Following are other terms and conditions that apply to this award. A more detailed set of terms and conditions will be included in the agreement document for funded projects.

Animal Use

LUNGevity allows animal use in biomedical research only when no other means of obtaining scientifically sound, valid, and useful results are available. Applicants must ensure that only the minimum number of appropriate animals required to obtain and validate results shall be used. In cases requiring the death of an animal, only the most appropriate and humane form of euthanasia shall be used consistent with the purpose of the research.

If animals will be used in the proposed research project, applicants must provide institutional endorsements that the research facility, its research, and its employees adhere to the appropriate animal welfare regulations in their country. In the U.S., these include:

- Animal Welfare Act
- USDA rules
- National Research Council *Guide for the Care and Use of Laboratory Animals*
- Public Health Service Policy on Humane Care and Use of Laboratory Animals

In addition to the above, applications must also include the following documents:

- Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC) accreditation.
- Institutional Animal Care and Use of Committee (IACUC) approval.

A project is **not** eligible for an award if the research proposal involves animals and the institution does not have accreditation from the Association for Assessment and Accreditation of Laboratory Animal Care International (AAALAC), **or** does not hold a current Public Health Service (PHS) Animal Welfare Assurance, **or** does not have accreditation from the United States

ASTRO-LUNGevity Residents/Fellows in Radiation Oncology Seed Grant 2025 Request for Application

Department of Agriculture, **or** does not have accreditation from the Institutional Animal Care and Use Committee (IACUC).

Authorized Award Holders
Awards are granted only to an individual; awards are not awarded to institutions. No award may be held by or transferred to another individual.

Biohazards
Biohazards are broadly defined to be recombinant and/or infectious and tumor materials that may be deleterious to normal organisms upon controlled exposure. Research involving biohazards requires one paper copy of the appropriate institutional committee approval at the time a full application is submitted.

Change in Budget
Requests for a change in budget that is 10% or more for a budget line requires prior approval by LUNGevity. All requests must be in writing and received by LUNGevity at least 60 days prior to the end of the current funding year. When requesting a change in budget, the awardee must indicate the amount to be transferred, the budget line the funds are currently included in and to where they would be transferred. In the case of supplies or equipment, all items must be itemized.

Change of Institution
Transfer of a LUNGevity award from one institution to another because of the relocation of the awardee requires prior approval by LUNGevity. All requests must be in writing and made as soon as the awardee officially knows of the relocation. A grant may not be transferred to a laboratory, clinic, hospital, or other research institution that is not affiliated with a tax-exempt not-for-profit institution. All unexpended funds must be returned to LUNGevity within 45 days of transfer approval. A grant agreement must then be executed by the new institution. After LUNGevity receives the unexpended funds from the original institution and the grant agreement has been executed with the new institution, the funds will be reissued to the new institution.

Equal Employment Opportunity
LUNGevity awards will be made to individuals working in institutions identified as Equal Opportunity Employers.

Equipment and Supply Purchases
Upon conclusion of the award, equipment and supplies purchased with award funds become the property of the institution at which the work was done.

Equipment Expenditures
Award monies will not be utilized to purchase equipment.

ASTRO-LUNGevity Residents/Fellows in Radiation Oncology Seed Grant 2025 Request for Application

Equipment Repair & Service Contracts
No portion of the award budget may be used for repair or service contract costs for institutional equipment.

Human Subjects
Whenever human subjects are a part of a LUNGevity-funded research project, the following documents must be received before any award monies are released:

- A copy of the Institutional Review Board (IRB) approval and approved patient consent forms
- A copy of the appropriate institutional committee approval for research involving human adult stem cells or use of human fetal tissue.

If the proposed research project involves human subjects, the population sampled shall be inclusive of the general population of relevance to the scientific question posed, without restriction in regard to gender, race, age, and socioeconomic status. Proposals that intentionally restrict the population sampled must include a compelling scientific rationale for such design.

LUNGevity encourages applicants to submit their projects to the appropriate human subjects Institutional Review Board at the time of application.

IRB approval and approved patient consent forms must be provided to LUNGevity before award funds will be disbursed.

Malpractice Liability
LUNGevity will not assume responsibility for and the institution will indemnify and hold LUNGevity harmless from any lawsuit, claim, judgment, damages, awards, or malpractice arising from research or investigations related to an award.

No-cost Extension
A no-cost award extension requires prior approval by LUNGevity. All requests must be in writing and received by LUNGevity at least 60 days prior to the award's official termination date. Requests that are not received at least 60 days prior to the award termination date **will not** be considered. When making the request, the awardee must provide a detailed rationale for the extension, project expenses to date, and a detailed revised budget. Awardees may request a no-cost extension only once per award. Approval of the no-cost extension is not automatic and will only be granted in exceptional circumstances.

Other Funding
LUNGevity research funds will not be awarded to duplicate any work that is being supported by other funding agencies.

ASTRO-LUNGevity Residents/Fellows in Radiation Oncology Seed Grant 2025 Request for Application

Overhead/Indirect Costs
Overhead or indirect costs are not permitted for this award.

Patent and Intellectual Property Policy
Inventions and discoveries from research performed during the term of a LUNGevity award will be subject to the current LUNGevity patent policy as well as to the patent policies of the institution where the work is performed.

Preprints and Public Access Policy
Grantees are required to deposit their submitted manuscripts, and subsequent versions, via a publicly accessible preprint server (e.g., arXiv, bioRxiv, medRxiv, or another trusted disciplinary server). Preprints must be shared under an open license (CC BY). LUNGevity Foundation recognizes preprints as evidence of productivity for purposes of grant applications, reviews, and reporting.

Upon acceptance, we require electronic copies of research papers, accepted for publication in a peer-reviewed journal and supported in whole or in part by LUNGevity Foundation, to be made freely available upon publication. Grantees may comply with this policy by publishing in an open access journal, publishing in a hybrid journal with an open access option, or by making a copy of their Author Accepted Manuscript available via a trusted open repository (e.g., PubMed Central). All peer-reviewed articles must be freely available under a suitable open license, preferably the Creative Commons Attribution (CC BY) license, which permits reuse without restriction.

Progress Reports
The Awardee and Sponsoring Institution must submit progress and financial reports at the end of the grant term, as well as any additional reports requested by LUNGevity during the grant term.

Project Support Expenditures
No award shall be used for the purchase of furniture or computers, repair or service contracts, institutional equipment, the construction or renovation of facilities, payment of honoraria or membership dues, tuition for either the awardee or other project personnel, the purchase of textbooks or periodicals, or payment for secretarial support.

Publication Expenditures
The maximum amount of funds expendable for publication costs is $2,500. All publication costs must directly relate to the LUNGevity project.

Publications and Conference Presentations
All publications and/or presentations at scientific conferences and meetings based on research conducted from this award must include a citation of LUNGevity as a supporting entity as follows: “This study was supported by a grant from LUNGevity Foundation.” Reprints of abstracts, manuscripts, or other articles that reflect research done after award acceptance must be submitted to LUNGevity.

ASTRO-LUNGevity Residents/Fellows in Radiation Oncology Seed Grant 2025 Request for Application

Tobacco-Funded Research
LUNGevity will not provide research or other funding to investigators who have received direct funding or funding from agencies of the tobacco industry.

Travel Expenditures
The maximum funds expendable for awardee travel are $1,500 per year.

APPLICATION ASSISTANCE
For questions regarding eligibility, policies, terms and conditions, or instructions for this application, please contact:

Jody Roosevelt
Research Program Coordinator
jroosevelt@LUNGevity.org

For help with proposalCENTRAL, please contact:

proposalCENTRAL Help Desk
pcsupport@altum.com
800-875-2562